Rosutin 20 Tablet

Before Treatment Initiation the Patient should be Placed on a Standard Cholesterol-Lowering Diet that should Continue During Treatment. The Dose should be Individualized According to the Goal of Therapy and Patient Response, Using Current ConsenSuspension Guidelines.
Treatment of Hypercholesterolemia: Patient of Asian Origin or with Risk Factors for Myopathy or Rhabdomyolysis: Initially 5 mg Once Daily Increased if Necessary to Max. 20 mg Daily.
Prevention of Cardiovascular Events: Patient of Asian Origin or with Risk Factors for Myopathy or Rhabdomyolysis: Initially 5 mg Once Daily Increased if Necessary to Max. 20 mg Daily.
Pediatric Use (Hyperlipidemia Including Familial Hypercholesterolemia): Child Younger than 6 Years: Not Recommended.
Child 6?9 Years: Initially 5 mg Daily, Increased if Necessary at Intervals of at Least 4 Weeks to Usual Max. 10 mg Once Daily.
Child 10?18 Years: Initially 5 mg Daily, Increased if Necessary at Intervals of at Least 4 Weeks to Usual Max. 20 mg Once Daily. [Reduced Dose Required with Concomitant Atazanavir, Darunavir, Ezetimibe, Fibrate, Itraconazole, Lopinavir, or Tipranavir] Use in the Elderly (>70 Years): A Start Dose of 5 mg is Recommended. No Dose Adjustment Necessary.
Renal Insufficiency: Initially 5mg Once Daily (Do not Exceed 20 mg Daily) if eGFR is 30-60 mL/minute/1.73 m2. Avoid if eGFR is Less Than 30 mL/minute/1.73 m2
Hepatic Impairment: Child-Pugh Scores of <7: No Increase in Systemic Exposure to Rosuvastatin. Child-Pugh Scores of 8 and 9: Increased Systemic Exposure has been Observed. In these Patients an Assessment of Renal Function should be Considered. Child-Pugh Scores >9: No Study.
Rosuvastatin is Contraindicated in Patients with Active Liver Disease.
Race: Increased Systemic Exposure has been Seen in Asian Subjects. The Recommended Starting Dose is 5 mg for Patients of Asian Ancestry. The 40 mg Dose is Contraindicated in these Patients.
Genetic Polymorphisms: Specific Types of Genetic Polymorphisms are Known that can Lead to Increased Rosuvastatin Exposure. For Patients who are Known to have Such Specific Types of Polymorphisms, a Lower Daily Dose of Rosuvastatin is Recommended.
Dosage in Patients with Pre-Disposing Factors to Myopathy: The Recommended Starting Dose is 5 mg in Patients with Predisposing Factors to Myopathy. The 40 mg Dose is Contraindicated in Some of these Patients.